ID   293T/ACE2 [Japan 2021]
AC   CVCL_B0XR
DR   Wikidata; Q108819503
RX   PubMed=33686154;
CC   Group: SARS-CoV-2 research cell line.
CC   Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33686154).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:13557; ACE2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P03070; SV40 large T antigen.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) (Note=tsA).
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0063 ! HEK293T
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 23-09-21; Last updated: 10-04-25; Version: 9
//
RX   PubMed=33686154; DOI=10.1038/s41598-021-84882-7; PMCID=PMC7940632;
RA   Uemura K., Sasaki M., Sanaki T., Toba S., Takahashi Y., Orba Y.,
RA   Hall W.W., Maenaka K., Sawa H., Sato A.;
RT   "MRC5 cells engineered to express ACE2 serve as a model system for the
RT   discovery of antivirals targeting SARS-CoV-2.";
RL   Sci. Rep. 11:5376.1-5376.9(2021).
//